Relapsed Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemia responds well to a combination of modified hyper‐CVAD, blinatumomab and tyrosine kinase inhibitor

Documenti analoghi

• Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia
  di: Céline Row, et al.
  Pubblicazione: (2024)
• Gene expression prognostic of early relapse risk in low‐risk B‐cell acute lymphoblastic leukaemia in children
  di: Xiaowen Gong, et al.
  Pubblicazione: (2024)
• Clinical significance of Philadelphia‐like‐related genes in a resource‐constrained setting of adult B‐acute lymphoblastic leukemia patients
  di: Keli Lima, et al.
  Pubblicazione: (2024)
• Durable MRD‐Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia
  di: Mohammad Shahzaib Qadir, et al.
  Pubblicazione: (2026)
• Effective treatment of relapsed/refractory CD19‐positive B/T‐type mixed‐phenotype acute leukemia with blinatumomab: A case report
  di: Masanori Aoki, et al.
  Pubblicazione: (2024)